Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. [electronic resource]
Producer: 20120824Description: 327-35 p. digitalISSN:- 1000-467X
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Asian People
- Breast Neoplasms -- drug therapy
- Capecitabine
- Class I Phosphatidylinositol 3-Kinases
- Deoxycytidine -- administration & dosage
- Diarrhea -- chemically induced
- Disease Progression
- Disease-Free Survival
- Exanthema -- chemically induced
- Female
- Fluorouracil -- administration & dosage
- Hand-Foot Syndrome -- etiology
- Humans
- Lapatinib
- Middle Aged
- Mutation
- Neoplasm Staging
- Phosphatidylinositol 3-Kinases -- genetics
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- metabolism
- Remission Induction
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.